companiesandmarkets.com

Return to Report | Print

Theratechnologies Inc - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/theratechnologies-inc-premium-company-profile-42822.asp

Report Summary

Introduction

Theratechnologies is a Canadian biopharmaceutical company developing therapeutic peptides for endocrine and metabolic disorders. The company has developed its product pipeline utilizing two technologies ExoPep and LAP (Long Acting Peptide).

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    The company’s pipeline products include: TH9507 being developed for HIV-Associated Lipodystrophy (Phase III); ThGRF being developed for growth hormone deficiency (Phase I), and cystic fibrosis (Phase I); and THG213.29 being developed for renal disease (preclinical).

    The company recognizes revenues in the form of royalties, and interest on investments from other pharmaceutical/biotechnology companies like ALZA pursuant to its co-development agreements.

    The company’s total revenues declined at a CAGR of 33.8% from $7.6 million to $1.5 million during the period 2002-2006. This represents an absolute decline of -$6.1 million for the period of analysis. The company derived its revenues from royalties, and interest on investments.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Overview 1
    Catalyst 1
    Summary 1
    Table of Contents 2
    Table of figures 3
    Table of tables 4
    Company Structure 5
    Company Overview and Key Facts 5
    Business Description 6
    Landmark Products and Services 6
    ExoPEP and LAP technologies 6
    History 7
    M&A History 8
    Pharma-G 8
    Company Financials 9
    Stock Market Performance 9
    P&L 11
    Balance Sheet 14
    Cash Flow 14
    Business Segment Performance 15
    Products & Services 16
    Pipeline Products 16
    In-house Pipeline 16
    TH9507 (tesamorelin) 16
    ThGRF 16
    THG213.29 16
    AC Forecast Product Sales 17
    Competitors and Strategic Business Relationships 19
    Key Competitors 19
    Key Suppliers 19
    Key Clients 20
    Strategy 21
    Company View 21
    Corporate Strategy 24
    SWOT Analysis 25
    Overview 25
    Strengths 26
    Acquisition of Pharma-G 26
    Weaknesses 27
    Discontinuation of ThGRF for other indications 27
    Weak product pipeline 27
    Opportunities 28
    TH9507 being developed for HIV-associated lipodystrophy 28
    Strategic alternatives 28
    Threats 29
    Lengthy and expensive regulatory process 29
    Value Chain Analysis 30
    Overview 30
    Discovery and Product Development 31
    Scorecard 32
    Overview 32
    Scorecard Analysis 33
    Key Employees 34
    List of Key Employees 34
    Key Employee Biographies 35
    Yves Rosconi 35
    Luc Tanguay 35
    Paul Pommier 35
    A Jean de Grandpré 36
    Gilles Cloutier 36
    Robert G Goyer 36
    Gérald A Lacoste 37
    Bernard Reculeau 37
    Jean-Denis Talon 37
    Pierre Caudrelier 38
    Marie-Noël Colussi 38
    Chantal Desrochers 38
    Jocelyn Lafond 39
    Christian Marsolais 39
    Martine Ortega 39
    Pierre Perazzelli 40
    Krishna Peri 40
    Andrea Gilpin 40
    Mark Reimer 41
    Financial and Operational Overview 42
    Financial and Operational Overview 42
    APPENDIX 44
    Ask the analyst 44
    Datamonitor consulting 44
    Disclaimer 44
    List of Tables
    Table 1: Theratechnologies - Key Facts 5
    Table 2: Theratechnologies - Year-End Share Price and Market Capitalization, 2002-2006 ($) 9
    Table 3: Theratechnologies - Key Events Impacting Share Price Performance 10
    Table 4: Theratechnologies - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
    Table 5: Theratechnologies - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
    Table 6: Theratechnologies - Balance Sheet, 2002-2006 ($ Mn) 14
    Table 7: Theratechnologies - Cash Flow, 2002-2006 ($ Mn) 14
    Table 8: Theratechnologies - Revenue Breakdown by Division, 2002-2006 ($ Mn) 15
    Table 9: Theratechnologies - In-house Pipeline Products 16
    Table 10: Theratechnologies - Forecast Sales, 2006-2010 ($ Mn) 17
    Table 11: Theratechnologies - Key Competitors 19
    Table 12: Theratechnologies - Key Suppliers 19
    Table 13: Theratechnologies - Key Clients 20
    Table 14: Theratechnologies - SWOT Analysis Summary 25
    Table 15: Theratechnologies - Value Chain Analysis 30
    Table 16: Theratechnologies - Scorecard 32
    Table 17: Theratechnologies - Key Employees 34
    Table 18: Theratechnologies - Financial and Operational Overview 42
    List of Figures
    Figure 1: Theratechnologies - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
    Figure 2: Theratechnologies - Key Strategic Revenues, 2006-2010 ($ Mn) 18